Literature DB >> 10484075

Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line.

L M Ching1, H A Young, K Eberly, C R Yu.   

Abstract

The antitumor agents flavone-8-acetic acid (FAA) and its dose-potent analogue 5,6-dimethylxanthenone-4-acetic acid (DMXAA), currently in clinical trials, have a novel mechanism of action that is mediated through their ability to induce a spectrum of cytokines. Since NFkappaB and STAT transcription factors participate in the regulation of a number of genes involved in immune and cytokine responses, we investigated whether these transcription factors were activated in the ANA-1 murine macrophage cell line by DMXAA and FAA compared with lipopolysaccharide (LPS), a bacterial component that induces an overlapping spectrum of cytokines. Activation of STAT1 and STAT3 was observed distinctly 4 hr after DMXAA and FAA stimulation. DMXAA and FAA induced NFkappaB translocation with slower kinetics of activation compared with LPS. STAT activation by DMXAA and FAA was inhibited by cycloheximide, indicating a requirement for de novo protein synthesis. The ANA-1 cells produced high titres of interferons (IFNs) in the culture supernatant after stimulation with DMXAA and FAA, and the addition of antibodies to IFNalpha/beta inhibited STAT activation, indicating that IFNs mediated STAT activation. NFkappaB activation, on the other hand, was not inhibitable with cycloheximide or with antibodies to IFNalpha/beta. NFkappaB activation appeared to be a direct action of the anticancer agents, whereas activation of the STAT proteins was due, in part, to the high titres of IFNs induced. These results demonstrate the significance of the IFN response in initiating the cascade of secondary events that may contribute to the overall antitumor efficacy of DMXAA and FAA in murine models.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10484075     DOI: 10.1016/s0006-2952(99)00194-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.

Authors:  Jing Sun; Liang-Chuan S Wang; Zvi G Fridlender; Veena Kapoor; Guanjun Cheng; Lai-Ming Ching; Steven M Albelda
Journal:  Biochem Pharmacol       Date:  2011-07-26       Impact factor: 5.858

2.  STING agonists induce an innate antiviral immune response against hepatitis B virus.

Authors:  Fang Guo; Yanxing Han; Xuesen Zhao; Jianghua Wang; Fei Liu; Chunxiao Xu; Lai Wei; Jian-Dong Jiang; Timothy M Block; Ju-Tao Guo; Jinhong Chang
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

3.  Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist.

Authors:  Xiaohui Zhang; Bowei Liu; Liudi Tang; Qing Su; Nicky Hwang; Mohit Sehgal; Junjun Cheng; Julia Ma; Xuexiang Zhang; Yinfei Tan; Yan Zhou; Zhongping Duan; Victor R DeFilippis; Usha Viswanathan; John Kulp; Yanming Du; Ju-Tao Guo; Jinhong Chang
Journal:  ACS Infect Dis       Date:  2019-05-14       Impact factor: 5.084

4.  Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  Joseph Conlon; Dara L Burdette; Shruti Sharma; Numana Bhat; Mikayla Thompson; Zhaozhao Jiang; Vijay A K Rathinam; Brian Monks; Tengchuan Jin; T Sam Xiao; Stefanie N Vogel; Russell E Vance; Katherine A Fitzgerald
Journal:  J Immunol       Date:  2013-04-12       Impact factor: 5.422

Review 5.  5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Authors:  Shufeng Zhou; Philip Kestell; Bruce C Baguley; James W Paxton
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

6.  Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.

Authors:  K Henare; L Wang; L-C S Wang; L Thomsen; S Tijono; C-J J Chen; S Winkler; P R Dunbar; C Print; L-M Ching
Journal:  Br J Cancer       Date:  2012-03-13       Impact factor: 7.640

7.  Using macrophage activation to augment immunotherapy of established tumours.

Authors:  Z G Fridlender; A Jassar; I Mishalian; L-Cs Wang; V Kapoor; G Cheng; J Sun; S Singhal; L Levy; S M Albelda
Journal:  Br J Cancer       Date:  2013-03-12       Impact factor: 7.640

8.  The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.

Authors:  Zachary J Roberts; Nadege Goutagny; Pin-Yu Perera; Hiroki Kato; Himanshu Kumar; Taro Kawai; Shizuo Akira; Ram Savan; David van Echo; Katherine A Fitzgerald; Howard A Young; Lai-Ming Ching; Stefanie N Vogel
Journal:  J Exp Med       Date:  2007-06-11       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.